MOC Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł8.87 |
| 52 Week High | zł22.50 |
| 52 Week Low | zł8.55 |
| Beta | 2.2 |
| 11 Month Change | -12.52% |
| 3 Month Change | -44.77% |
| 1 Year Change | -48.73% |
| 33 Year Change | -77.37% |
| 5 Year Change | -11.30% |
| Change since IPO | -69.41% |
Recent News & Updates
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?
Aug 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Shareholder Returns
| MOC | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -11.5% | -5.4% | -3.3% |
| 1Y | -48.7% | 40.0% | 1.1% |
Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned 40% over the past year.
Return vs Market: MOC underperformed the Polish Market which returned 1.1% over the past year.
Price Volatility
| MOC volatility | |
|---|---|
| MOC Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: MOC has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: MOC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 105 | Marcin Szumowski | molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| MOC fundamental statistics | |
|---|---|
| Market cap | zł148.49m |
| Earnings (TTM) | -zł30.75m |
| Revenue (TTM) | zł1.52m |
98.1x
P/S Ratio-4.9x
P/E RatioIs MOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOC income statement (TTM) | |
|---|---|
| Revenue | zł1.52m |
| Cost of Revenue | zł3.24m |
| Gross Profit | -zł1.72m |
| Other Expenses | zł29.04m |
| Earnings | -zł30.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -112.84% |
| Net Profit Margin | -2,020.94% |
| Debt/Equity Ratio | 0% |
How did MOC perform over the long term?
See historical performance and comparison